Q4 25 EPS
$-0.78
MISS 34.88%
Est. $-0.58
Q4 25 Revenue
$68.7M
BEAT +6.15%
Est. $64.7M
vs S&P Since Q4 25
+2.1%
BEATING MARKET
SNDX +11.3% vs S&P +9.2%
Full Year 2025 Results
FY 25 EPS
$-3.29
FY 25 Revenue
$172.4M
Market Reaction
Did SNDX Beat Earnings? Q4 2025 Results
Syndax Pharmaceuticals capped a transformative year with a strong commercial quarter, reporting Q4 2025 revenue of $68.73 million against a net loss of $0.78 per share, as its twin FDA-approved therapies continued to gain meaningful clinical traction… Read more Syndax Pharmaceuticals capped a transformative year with a strong commercial quarter, reporting Q4 2025 revenue of $68.73 million against a net loss of $0.78 per share, as its twin FDA-approved therapies continued to gain meaningful clinical traction. The primary engine of that growth was Revuforj, which generated $44.20 million in Q4 net product revenue, a 38% sequential increase fueled by the October 2025 label expansion into NPM1-mutated AML and a 35% quarter-over-quarter rise in total prescriptions to roughly 1,150. Niktimvo, co-commercialized with Incyte for chronic GVHD, contributed an additional $19.39 million to Syndax's share of collaboration profit. Full-year 2025 revenue reached $172.35 million, up sharply from $23.68 million in 2024, underscoring just how rapidly the company has pivoted from development to commercial stage. Looking ahead, management guided combined R&D and SG&A expenses of approximately $400 million for 2026, while expressing confidence that growing product revenues and a stable cost base will carry the company to profitability without requiring additional capital raises.
Key Takeaways
- • Revuforj Q4 net revenue increased 38% quarter-over-quarter driven by October 2025 FDA approval expanding label to R/R NPM1m AML
- • Total Revuforj prescriptions grew approximately 35% quarter-over-quarter to approximately 1,150 in Q4
- • Niktimvo net revenue grew 22% quarter-over-quarter to $56.0 million in Q4
- • Growing adoption of Revuforj in R/R NPM1m AML with early indicators suggesting ≥30% of new patient starts were NPM1 in Q4
- • Approximately 90% of U.S. BMT centers have ordered Niktimvo
- • 60-70% of patients who started Niktimvo in Q1 2025 remained on therapy at month 10
- • Growing combination use of Revuforj with approximately 40% of use in combination
- • Approximately 70% of Revuforj use in second/third line treatment
SNDX YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
SNDX Revenue by Segment
With YoY comparisons, source: SEC Filings
“We solidified our leadership position and proved the strength of Syndax's R&D and commercial capabilities in 2025, achieving our third FDA approval and successfully launching two first- and best-in-class medicines. We reached thousands of patients with Revuforj and Niktimvo and generated over $275 million in 2025 sales, rapidly advancing the company towards profitability.”
— Michael A. Metzger, Q4 2025 Earnings Press Release
SNDX Earnings Trends
SNDX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
SNDX EPS Trend
Earnings per share: estimate vs actual
SNDX Revenue Trend
Quarterly revenue: estimate vs actual
SNDX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.59 | $-0.48 | +18.75% | $64.9M | -7.11% |
| Q4 25 MISS FY | $-0.58 | $-0.78 | -34.88% | $68.7M | +6.15% |
| FY Full Year | — | $-3.29 | — | $172.4M | — |
| Q3 25 BEAT | $-0.71 | $-0.70 | +1.55% | $45.9M | -4.38% |
| Q2 25 BEAT | $-1.01 | $-0.83 | +17.50% | $38.0M | +42.48% |
| Q1 25 BEAT | $-1.27 | $-0.98 | +23.04% | $20.0M | +23.87% |